Education and Support

Female customer support specialist

Starting treatment with IMBRUVICA® can feel like a big step. That’s why the YOU&i™ Support Program offers the information and tools you may need during treatment.

What You Need, When You Need It

Choose education and support options designed to help you throughout your treatment with IMBRUVICA®.

YOU&i™ Support Communications

You can sign up to receive educational emails throughout the different stages of your treatment.

Emails include tips and information about

  • Talking to your healthcare team
  • Asking friends and family for help
  • Setting goals and celebrating successes
  • Coping with and adjusting to treatment

These emails also provide important information and reminders about IMBRUVICA® that can help you know what to expect during treatment.

YOU&i™ Nurse Educators

You can talk to a YOU&i™ Nurse Educator on the phone if you have questions about your treatment with IMBRUVICA®.

YOU&i™ Nurse Educators can answer questions such as

  • What do I do if I miss a dose of IMBRUVICA®?
  • What are the possible side effects of IMBRUVICA®?
  • Are there any foods I should avoid while taking IMBRUVICA®?
  • What questions should I ask my doctor?

YOU&i™ Nurse Educators are experts on IMBRUVICA®, but your healthcare team are experts on your care. YOU&i™ Nurse Educators do not replace medical advice from your doctor and will direct you to your healthcare team if you have a specific question about your treatment.

IMBRUVICA® blue phone icon

Speak with a YOU&i™ Nurse Educator:
1-877-877-3536 | Menu Option 2
Monday-Friday, 8:00 AM-8:00 PM and Saturday 8:00 AM-5:00 PM ET
Los enfermeros instructores pueden ofrecer información de IMBRUVICA® en español.

Be Your Own Advocate

Many people have questions during treatment, and it’s important to get them answered. Click or tap on the following questions to get some tips that may help. To receive more information about topics like these, sign up for the YOU&i™ Support Program.

    IMBRUVICA® blue chat symbol

    Try this tip:

    Write down your questions before your appointment to help you make sure you ask them all. You can also take notes to help you remember your doctor’s answers.

    Elderly man with glasses
    IMBRUVICA® blue repeat icon

    Try this tip:

    Take IMBRUVICA® at the same time you do something else every day, like when you brush your teeth. Remember, it’s important to take your medication at about the same time each day and exactly as directed by your doctor.1

    Smiling elderly man
    Reference

    1. Patient Information. IMBRUVICA® (ibrutinib) Prescribing Information. Pharmacyclics, LLC 2019.

    Try this tip:

    Break down a big goal into smaller steps that you can work on each day. Reaching a big goal feels easier when you achieve small successes over time.

    Smiling elderly woman

    Try this tip:

    Build a network of friends and family who can help or find a support group near you. Find out more about support groups.

    Elderly man on computer

    Resources and Tools

    Check out the resources below and visit the IMBRUVICA® Resource Library to download planners, calendars, and information sheets that can help you engage with your treatment right away.

    IMBRUVICA® Starter Kit

    When you started IMBRUVICA®, your doctor or specialty pharmacy may have given you an IMBRUVICA® starter kit. This packet helps you set up your routine with IMBRUVICA®—from tracking symptoms and side effects to staying motivated during treatment. If you did not receive a starter kit, a YOU&i™ Nurse Educator can mail one to you. Call 1-877-877-3536 to request one today.

    Medisafe for IMBRUVICA®

    This free smartphone app for iOS or Android can remind you to take IMBRUVICA® exactly as your doctor prescribed. You can sign up to receive information about IMBRUVICA®, too.

    Learn More About the Medisafe App
    YOU&i Support Program Logo (white)

    No matter where you are with your IMBRUVICA® treatment, the YOU&i™ Support Program is here to help.

    Sign Up for Support

    If you haven’t been prescribed IMBRUVICA® yet, visit www.imbruvica.com to learn more about IMBRUVICA® as a potential treatment option.

    IMPORTANT SIDE EFFECT INFORMATION

    Before taking IMBRUVICA®, tell your healthcare provider about all of your medical conditions, including if you:

    • have had recent surgery or plan to have surgery. Your healthcare provider may stop IMBRUVICA® for any planned medical, surgical, or dental procedure.
    • have bleeding problems.
    • have or had heart rhythm problems, smoke, or have a medical condition that increases your risk of heart disease, such as high blood pressure, high cholesterol, or diabetes.
    • have an infection.
    • have liver problems.
    • are pregnant or plan to become pregnant. IMBRUVICA® can harm your unborn baby. If you are able to become pregnant, your healthcare provider will do a pregnancy test before starting treatment with IMBRUVICA®.
      • Females should not become pregnant during treatment and for 1 month after the last dose of IMBRUVICA®.
      • Males should avoid getting female partners pregnant during treatment and for 1 month after the last dose of IMBRUVICA®.
    • are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will take IMBRUVICA® or breastfeed.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works and can cause side effects.

    How should I take IMBRUVICA®?

    • Take IMBRUVICA® exactly as your healthcare provider tells you to take it.
    • Take IMBRUVICA® 1 time a day.
    • Swallow IMBRUVICA® capsules and tablets whole with a glass of water.
    • Do not open, break, or chew IMBRUVICA® capsules.
    • Do not cut, crush, or chew IMBRUVICA® tablets.
    • Take IMBRUVICA® at about the same time each day.
    • If you miss a dose of IMBRUVICA® take it as soon as you remember on the same day. Take your next dose of IMBRUVICA® at your regular time on the next day. Do not take extra doses of IMBRUVICA® to make up for a missed dose.
    • If you take too much IMBRUVICA®, call your healthcare provider or go to the nearest hospital emergency room right away.

    What should I avoid while taking IMBRUVICA®?

    • You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges (often used in marmalades) during treatment with IMBRUVICA®. These products may increase the amount of IMBRUVICA® in your blood.

    What are the possible side effects of IMBRUVICA®?

    IMBRUVICA® may cause serious side effects, including:

    • Bleeding problems (hemorrhage) are common during treatment with IMBRUVICA® and can also be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs of bleeding, including: blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding or bleeding that is severe or that you cannot control, vomit blood or vomit looks like coffee grounds, cough up blood or blood clots, increased bruising, dizziness, weakness, confusion, change in your speech, or a headache that lasts a long time.
    • Infections can happen during treatment with IMBRUVICA®. These infections can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, weakness, confusion, or other signs or symptoms of an infection during treatment with IMBRUVICA®.
    • Decrease in blood cell counts. Decreased blood counts (white blood cells, platelets, and red blood cells) are common with IMBRUVICA®, but can also be severe. Your healthcare provider should do monthly blood tests to check your blood counts.
    • Heart rhythm problems (ventricular arrhythmias, atrial fibrillation and atrial flutter). Serious heart rhythm problems and death have happened in people treated with IMBRUVICA®, especially in people who have an increased risk for heart disease, have an infection, or who have had heart rhythm problems in the past. Tell your healthcare provider if you get any symptoms of heart rhythm problems, such as feeling as if your heart is beating fast and irregular, lightheadedness, dizziness, shortness of breath, chest discomfort, or you faint. If you develop any of these symptoms, your healthcare provider may do a test to check your heart (ECG) and may change your IMBRUVICA® dose.
    • High blood pressure (hypertension). New or worsening high blood pressure has happened in people treated with IMBRUVICA®. Your healthcare provider may start you on blood pressure medicine or change current medicines to treat your blood pressure.
    • Second primary cancers. New cancers have happened during treatment with IMBRUVICA®, including cancers of the skin or other organs.
    • Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.

    The most common side effects of IMBRUVICA® in adults with B-cell malignancies (MCL, CLL/SLL, WM and MZL)  include:

    • Diarrhea
    • Muscle and bone pain
    • Rash
    • Bruising
    • Nausea
    • Tiredness
    • Fever

    The most common side effects of IMBRUVICA® in adults with cGVHD include:

    • Tiredness
    • Bruising
    • Diarrhea
    • Mouth sores (stomatitis)
    • Muscle spasms
    • Nausea
    • Pneumonia

    Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of fluids during treatment with IMBRUVICA® to help reduce your risk of losing too much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you have diarrhea that does not go away.

    These are not all the possible side effects of IMBRUVICA®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. 

    General information about the safe and effective use of IMBRUVICA®

    Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA® for a condition for which it was not prescribed. Do not give IMBRUVICA® to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA® that is written for health professionals.

    Please see the full Important Product Information.

    INDICATIONS

    What is IMBRUVICA® (ibrutinib)?

    IMBRUVICA® (ibrutinib) is a prescription medicine used to treat adults with:

    • Mantle cell lymphoma (MCL) who have received at least one prior treatment
    • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
    • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion
    • Waldenström's macroglobulinemia (WM)
    • Marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment
    • Chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy 

    It is not known if IMBRUVICA® is safe and effective in children.

    IMPORTANT SIDE EFFECT INFORMATION

    INDICATIONS

    Your use of the information on this site is subject to the terms of the Legal Notice and new Privacy Policy of Pharmacyclics LLC. This site is published by Pharmacyclics LLC which has developed the content in conjunction with Janssen Biotech, Inc. Any information that is collected on this site may be shared between Pharmacyclics LLC and Janssen Biotech, Inc. This information is intended for use by our customers, patients, and healthcare professionals in the United States and Puerto Rico only. Pharmacyclics LLC recognizes that the Internet is a global communication medium; however laws, regulatory requirements, and medical practices vary from country to country.

    IMBRUVICA® (ibrutinib) is covered by U.S. Patents, which are listed in FDA's Orange Book (available at https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm).

    © Pharmacyclics LLC 2019 © Janssen Biotech, Inc. 2019 09/19 PRC-05568